Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation | Zendy

Maria V. Barabanshikova | Zendy; Igor Nikolaevich Zubarovsky | Zendy; V M Savrasov | Zendy; Andrey Jurjevich Korolkov | Zendy; Vadim Baykov | Zendy; Anna Botina | Zendy; Julia J. Vlasova | Zendy; Ivan Moiseev | Zendy; Elena I. Darskaya | Zendy; Elena Morozova | Zendy; Boris V. Afanasyev | Zendy

Open Access

Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation

Author(s) -

Maria V. Barabanshikova,

Igor Nikolaevich Zubarovsky,

V M Savrasov,

Andrey Jurjevich Korolkov,

Vadim Baykov,

Anna Botina,

Julia J. Vlasova,

Ivan Moiseev,

Elena I. Darskaya,

Elena Morozova,

Boris V. Afanasyev

Publication year - 2019

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2019.03.001

Subject(s) - medicine , splenectomy , myelofibrosis , surgery , ruxolitinib , portal vein thrombosis , transplantation , gastroenterology , sepsis , thrombosis , thrombotic microangiopathy , debulking , spleen , cancer , disease , ovarian cancer , bone marrow

Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only treatment option with curative potential in patients with myelofibrosis (MF). The aim of our study was to evaluate the safety of splenectomy before alloHSCT in MF patients who failed to achieve significant spleen response after ruxolitinib therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research